3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management

Overview

Journal J Crohns Colitis

Publisher Oxford University Press

Date 2016 Sep 24

PMID 27660341

Citations 742

Authors

Fernando Gomollon

Axel Dignass

Vito Annese

Herbert Tilg

Gert Van Assche

James O Lindsay

Laurent Peyrin-Biroulet

Garret J Cullen

Marco Daperno

Torsten Kucharzik

Florian Rieder

Sven Almer

Alessandro Armuzzi

Marcus Harbord

Jost Langhorst

Miquel Sans

Yehuda Chowers

Gionata Fiorino

Pascal Juillerat

Gerassimos J Mantzaris

Fernando Rizzello

Stephan Vavricka

Paolo Gionchetti

Affiliations

Soon will be listed here.

Abstract

This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016].

Citing Articles

Genetic Polymorphisms (ApaI, FokI, BsmI, and TaqI) of the Vitamin D Receptor (VDR) Influence the Natural History and Phenotype of Crohn's Disease.

Kafentzi T, Tsounis E, Tourkochristou E, Avramopoulou E, Aggeletopoulou I, Geramoutsos G Int J Mol Sci. 2025; 26(5).

PMID: 40076474 PMC: 11899612. DOI: 10.3390/ijms26051848.

Fibrinogen-to-albumin ratio: a new biomarker to identify inflammatory bowel disease in active stage.

Chen X, Huang Z, Huang X Front Med (Lausanne). 2025; 12:1460975.

PMID: 40046919 PMC: 11879998. DOI: 10.3389/fmed.2025.1460975.

Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment.

Atay A, Cagir Y, Ergul M, Ozturk O, Durak M, Yuksel I J Clin Med. 2025; 14(4).

PMID: 40004757 PMC: 11857063. DOI: 10.3390/jcm14041228.

Risk factors and clinical characteristics of colonization and infection in patients with inflammatory bowel disease exposed to Vedolizumab: a multicenter retrospective study.

Li Q, Song X, Su P, Lv X, Liu X, Chen X Therap Adv Gastroenterol. 2025; 18:17562848251321707.

PMID: 39975482 PMC: 11837063. DOI: 10.1177/17562848251321707.

RISE-MX, a real-world study of patients with moderate/severe inflammatory bowel disease returning for hospital follow-up in Mexico: baseline demographics and clinical characteristics, treatment and disease status.

Martinez-Vazquez M, Bosques-Padilla F, Miranda-Cordero R, Yamamoto-Furusho J Therap Adv Gastroenterol. 2025; 18:17562848251318857.

PMID: 39968532 PMC: 11833814. DOI: 10.1177/17562848251318857.